• Explore /
  • Poster
  • / ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer.

ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer.

Abstract Poster

Authors

null

Thorsten Goetze

Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, UCT-University Cancer Center and Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Frankfurt Am Main, Germany

Thorsten Goetze , Regina Eickhoff , Miriam Pons , Lisa Kochen , Doerthe Vortmeyer , Salah-Eddin Al-Batran , Timursah Habibzade , Marius Adler , Maria A Gonzalez-Carmona , Thomas Jens Ettrich , Claus-Henning Koehne , Daniel Pink , Florian van Boemmel , Ursula Pession , Thomas Wehler , Dominik Paul Modest

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05239169

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr TPS583)

DOI

10.1200/JCO.2024.42.3_suppl.TPS583

Abstract #

TPS583

Poster Bd #

P12

Abstract Disclosures

Similar Posters

First Author: Thorsten Oliver Goetze

First Author: Viktor Grünwald

First Author: Ho Yeong Lim

First Author: Edward B. Garon